Doshi and colleagues have conducted a retrospective claims analysis (2009 through 2012) of psoriasis patients on Medicare to examine the use and adherence to those initiating treatment with either infliximab, etanercept, adalimumab, or ustekinumab.
All News
Like other extraarticular manifestations, rheumatoid (RA) or connective tissue disease (CTD) related interstitial lung disease (ILD) is difficult to identify early and equally challenging to treat.
It is important to know where you’ve been, as it will most certainly color where you are going. Hence, in honor of our 1st year anniversary, we have taken note of our most popular articles.
Doctors have an interesting problem. They have an ingrained professional obsessive-compulsive habit; they fixate on the care of individual patients and on the science of healing. This is an admirable trait; it results in high-quality care. However, when physicians need to change their attention from healer to leader, from medicine to the business of medicine, from healthcare to the healthcare system, they falter. Stuck in silos, they fail to adjust their focus. They resist systemic innovation. Because they cannot flip, they flop.
Watch Dr. Jack Cush cover ten highlights from this week on RheumNow.com.
Numerous guidelines (ACR, ACIP/CDC, ATS, NICE) all call for timely vaccinations in patients with rheumatoid arthritis (RA) and those receiving immunosuppressives or biologics.
Alpha defensins are released following apoptosis, necrosis, or netosis of human neutrophils. They are taken up by other cells and microbes, wherein they permeablize membranes and kill microbes and host cells. Thus, they augment the antimicrobial capacity of macrophages and at the same time inhibit the biosynthesis of proinflammatory cytokines.
Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disorder with many associations or causative factors that rarely includes autoimmune disorders and lupus.
Amidst a stringent regulatory environment, and with the rising use and abuse of narcotics and increasing regulation limiting narcotic analgesic use, the FDA approved (August 2015) the use of extended-release oxycodone in children (11 to 16 years old) with severe, "around-the-clock" pain
Markusse and investigators from The Netherlands have reported their 10 year results of treating early rheumatoid arthritis (RA) patients using targeted treatment strategies.
Harvey and coworkers reported the results of subjects followed in the Reykjavik study, demonstrating that a first osteoporotic fracture was followed by an increased risk for a second fracture, both immediately and over time.
Choi and colleagues analyzed US hospitalizations (2009–2013) to assess the frequency and racial distribution of patients hospitalized with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) related to the use of urate-lowering (ULT) therapy (predominantly allopurinol).
Danish researchers studied a cohort of 59,423 mild psoriasis and 11,566 severe psoriasis patients over a 14 year period, and found 240 and 50 cases of abdominal aortic aneurysms (AAA), repectively. (Citation source http://buff.ly/1YxGpDA)
Patients with systemic lupus erythematosus are at risk of cardiovascular events early in the course of disease -- and even before their lupus is diagnosed, an international study found.
Video recap of highlights from this week at RheumNow.com.
Three articles (2 studies, 1 commentary) in this week's issue of NEJM tackle the issue of whether fusion adds anything to long-term outcomes in those undergoing decompression for lumbar spinal fusion.
Major advances in biosimilars have occurred in the last three months, beginning with the FDA Arthritis Advisory Committee voting 21-3 to approve Celltrion’s Inflectra (CT-P13) and ending with the recent approval of Inflectra (generically referred to as infliximab dyyb).
Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers. While the diagnosis is easy, the disease course and management can be complicated and challenging.
One of the hallmarks of aggressive rheumatoid arthritis (RA) is presence of antibodies against citrullinated protein antigens (ACPA).
In a retrospective cohort comparison study, 42,180 rheumatoid arthritis (RA) patients were compared 1:4 with 168,000 normal controls to examine the incidence of new tuberculosis in Taiwan. The RA population included those receiving csDMARDs (36,162), etanercept (3,577), adalimumab (1,67
